Background: COVID-19 is still a global health issue, there
is limited evidence in South America regarding laboratory
biomarkers associated with severe disease. The objective of
our study was to identify hematological and hemostatic
changes associated with severe COVID-19.
Methods: A total of 170 hospitalized patients with COVID-
19 were included in the study, defining their severity
according to established criteria. Demographic, clinical,
and laboratory (days 1, 3, 7, 15) data were obtained. We
performed a statistical analysis, assuming significance with
a value of p < 0.05. We analyzed the correlation between
severity and biomarkers and established cut-off values for
severe patients through ROC curves, estimating Odds Ratio
associated with severe disease.
Results: Day 1 was observed significant differences
between moderate vs severe patients for leukocytes (WBC),
Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte